Abstracts tagged "Calgranulin"

Abstract Number: 1119 • 2016 ACR/ARHP Annual Meeting
The Enhanced Expression of mRNA for Calgranulins, S100A8, S100A9 and S100A12, in CD34+ Cells of the Bone Marrow in Rheumatoid Arthritis
Tatsuo Nagai¹, Yu Matsueda², Tetsuya Tomita³, Hideki Yoshikawa³ and Shunsei Hirohata², ¹Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan, ²Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan, ³Department of Orthopedics, Osaka University Graduate School of Medicine, Suita Osaka, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory arthritis of unknown etiology. A subset of S100 proteins known as calgranulins (S100A8, S100A9 and S100A12) are…
Abstract Number: 3037 • 2016 ACR/ARHP Annual Meeting
Calprotectin Is Highly Upregulated in Inflamed Axial Entheses in SKG Mice
Zheni Stavre¹, Yukiko Maeda² and Ellen M. Gravallese³, ¹Internal Medicine-Rheumatology, University of Massachusetts Medical School, Worcester, MA, ²Medicine, University of Massachusetts Medical School, Worcester, MA, ³Lazare Research Bldg, University of Massachusetts Medical School, Worcester, MA
Background/Purpose: SKG mice exhibit features of spondyloarthropathy (SpA) and inflammatory bowel disease (IBD). Their SpA-like phenotype is induced by a beta-glucan, curdlan, via the Dectin-1…
Abstract Number: 79 • 2013 ACR/ARHP Annual Meeting
Synovial Activation In Experimental OA Drives Immuno suppressive Effects Of Adipose-derived Stem Cells After Local Administration and Protects Against Chondrogenesis In Ligaments
Peter L.E.M. van Lent¹, Rik Schelbergen¹, Menno C. ter Huurne², Arjen B. Blom¹, Johannes Roth³, Thomas Vogl⁴, Christian Jorgensen⁵ and Wim B. van den Berg⁶, ¹Rheumatology Research & Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Immunology, Institute of Immunology University of Muenster, Muenster, Germany, ⁴Institute of Immunology, University of Muenster, Muenster, Germany, ⁵Department of therapy & Immuno-Rhumatology, Inserm U844, CHU saint-Eloi, Université Montpellier 1, CHU Lapeyronie, Montpellier, France, ⁶Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: A substantial subpopulation of patients with early osteoarthritis (OA) show a thickened synovial lining layer comprising macrophages expressing an activated phenotype (reflected by production of…
Abstract Number: 2291 • 2012 ACR/ARHP Annual Meeting
Enhanced Release of S100A9 and Hepatocyte Growth Factor by the Epidermis in Systemic Sclerosis
Joanna Nikitorowicz Buniak¹, Christopher P. Denton¹, David J. Abraham² and Richard J. Stratton¹, ¹Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, ²UCL Medical School, London, United Kingdom
Background/Purpose: Systemic sclerosis (SSc) is a severe disease of unknown aetiology characterised by cellular injury and activation in early stage, followed by autoimmunity and fibrosis.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].